Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 18/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CDK2AP1 | O14519 | 2/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8835231 | 0.95 | CHEK1 (0.49) | CHEK1KCNH2CDK2AP1 | |
| SCHEMBL27768326 | 0.89 | CHEK1 (0.68) | CHEK1KCNH2CDK2AP1 | |
| SCHEMBL4343133 | 0.89 | CHEK1 (0.68) | CHEK1KCNH2CDK2AP1 | |
| SCHEMBL29900038 | 0.89 | CHEK1 (0.68) | CHEK1KCNH2CDK2AP1 | |
| SCHEMBL29900120 | 0.89 | CHEK1 (0.68) | CHEK1KCNH2CDK2AP1 | |
| SCHEMBL12948509 | 0.89 | CHEK1 (0.56) | CHEK1CDK2AP1ACP1 | |
| Hydrochloric Acid SCHEMBL27747351 | 0.89 | CHEK1 (0.67) | CHEK1KCNH2CDK2AP1 | |
| SCHEMBL14997524 | 0.86 | CHEK1 (0.41) | CHEK1KCNH2CDK2AP1ACP1 | |
| SCHEMBL12921985 | 0.86 | CHEK1 (0.42) | CHEK1KCNH2 | |
| SCHEMBL8828298 | 0.85 | CHEK1 (0.42) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962626-B2 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2015-02-24 | — | — | US | disclosed |
| EP-2241569-B1 | THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES | ZHEJIANG MED XINCHANG PHARM (CN) | 2012-05-23 | — | — | EP | disclosed |
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | WU, ZHANGGUI (CN) | 2011-01-13 | — | — | US | disclosed |
| EP-2241569-A1 | THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2010-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | CYP3A5, ABCC5, DPYD | CHEK1 2344/4885KCNH2 195/4885CDK2AP1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.